TNDM — Tandem Diabetes Care Cashflow Statement
0.000.00%
- $1.20bn
- $1.11bn
- $940.20m
- 70
- 40
- 44
- 50
Annual cashflow statement for Tandem Diabetes Care, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -34.4 | 15.6 | -94.6 | -223 | -96 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 87.3 | 67.6 | 135 | 193 | 115 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -36.6 | 14.4 | -4.65 | -17.7 | -11.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 24.7 | 111 | 50.5 | -31.8 | 24.2 |
Capital Expenditures | -32.3 | -23.5 | -43 | -51.6 | -65.6 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -264 | -163 | 76.1 | -34.1 | 42.2 |
Acquisition of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -296 | -187 | 33.2 | -85.7 | -23.5 |
Financing Cash Flow Items | — | — | -0.675 | -0.071 | -15.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 314 | 51.9 | 16.9 | 4.11 | 8.37 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 43.4 | -23.4 | 101 | -114 | 10.4 |